What we know about a new health data tracking system being announced by White House
The collaboration between the federal government and Big Tech would allow patients to more seamlessly track and share their medical records or data among doctors, hospital systems and health apps, the administration and participating companies say.
Details of the system were announced Wednesday during a White House event dubbed 'Making Health Technology Great Again.'
The system would be maintained by the federal government through the Centers for Medicare and Medicaid Services, pulling health data kept by Big Tech companies like Amazon, Google and Apple as well as major health companies like hospital system Cleveland Clinic and insurer UnitedHealth Group. Patients will need to opt in to have their medical records and data shared, which CMS says will be kept secure.
Once a patient is in the system, their information could be shared across apps or health systems that have joined the initiative. So, for example, the Apple Health app on your iPhone that tracks your daily step count or your sleep could access lab results from your doctor's office. Putting that information together, the Trump administration says, will offer a fuller picture of your health.
Apps and AI technology could also help people make better choices at the grocery store or identify patterns in their day-to-day life that might be affecting their health, said U.S. Health and Human Services Secretary Robert F. Kennedy Jr. during Wednesday's White House event.
'Now if you have your medical records, you can get personalised advice," Kennedy said.
Currently, there's no unified database where a person's health data and medical records are kept. Each health system stores, shares and releases patients' records in different ways. That's a big reason a lot of systems still rely on fax machines, because it's a guaranteed way to share records between offices and hospitals. Faxing is also a secure way to send information that complies with federal privacy laws.
Some health networks also have their own apps, electronic systems or websites that allow patients to look up their records online or share information with other providers.
The U.S. Department of Health and Human Services says that 60 companies have signed on to work with the system and that they have pledged to 'deliver results to the American people in the first quarter of 2026.'
The Trump administration, however, made a similar proposal back in 2018 that never fully came to fruition.
Patient advocates and ethicists say many may worry about how their health information — something Americans have long carefully guarded — could be used in ways that they don't want or expect.
'There are enormous ethical and legal concerns,' said Lawrence Gostin, a Georgetown University law professor who specialises in public health. 'Patients across America should be very worried that their medical records are going to be used in ways that harm them and their families.'
Also, digital privacy advocates say they are skeptical that patients will be able to count on their data being stored securely.
'This scheme is an open door for the further use and monetisation of sensitive and personal health information,' said Jeffrey Chester at the Center for Digital Democracy.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India Today
3 hours ago
- India Today
Slash US drug prices or face action: Trump pressures CEOs of 17 pharma companies
US President Donald Trump has issued a direct ultimatum to 17 of the world's largest pharmaceutical companies, demanding they lower the price of prescription drugs for Americans or face a move announced by the White House on Thursday, Trump sent signed letters to the CEOs of top drugmakers urging them to extend the 'most favoured nation' pricing model to Medicaid and return excess overseas profits to US patients and posted individual letters he had sent to 17 drugmakers, including Pfizer, Merck, and Johnson & Johnson, on his Truth Social account. The letters set a deadline of September 29 for the companies to provide binding commitments to these demands. 'According to recent data, the prices that Americans have been paying for brand name drugs are more than three times the price other similarly developed nations pay,' said White House Press Secretary Karoline letters come after Trump signed an executive order in May, reviving a contentious plan, known as the 'most favored nation' policy, that aims to slash drug costs by tying the prices of some medicines in the US to the significantly lower ones abroad.'We will deploy every tool in our arsenal to end these practices,' Leavitt details of enforcement remain unclear, Trump's aggressive messaging marks a return to populist themes that defined his earlier administration, with drug prices once again taking center stage in his political agenda.'The president is calling on the companies to extend most favoured nation pricing to Medicaid... and return excess overseas revenue to American patients and taxpayers,' said the White House say such pricing mandates could lead to supply disruptions or discourage innovation, but Trump's team maintains that US consumers have been unfairly burdened for decades.- EndsWith inputs from Reuters
NDTV
6 hours ago
- NDTV
Trump Warns Pharma Companies To Cut Prices Or Be Punished
Washington: US President Donald Trump told major pharmaceutical firms Thursday to lower prices or face punishment, as he moved to give Americans relief from medicine costs much higher than elsewhere in the world. In letters to 17 drug companies published on his Platform Truth Social, Trump said he wants the firms to work with his administration to institute a series of changes within 60 days. "If you refuse to step up we will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices," Trump wrote without specifying what the consequences would entail. Trump is following up an on executive order he signed in May to address US drug prices that are among the highest in the world -- more than three times what people in similarly developed countries pay, the White House said Thursday. In the letters Trump said the response he has received so far to his order from companies have been "more of the same: shifting blame" and policy changes that would in fact benefit the industry, not consumers. Key to the Trump plan is a "Most Favored Nation" policy that pins the cost of drugs sold in the United States to the lowest price paid by other countries for the same drug. Trump said Thursday he wants the companies to extend this pricing policy to medications used by older people under the government-backed health program Medicaid. He also wants this status to apply to new drugs, Trump said in the letters. "Americans are demanding lower drug prices and they need them today," Trump wrote.
Hindustan Times
7 hours ago
- Hindustan Times
Indian firms aim to gorge on weight-loss drugs
Until recently, Indians had few safe ways of joining the global craze for weight-loss drugs. Some smuggled them into the country when returning home from abroad; others chanced it with bootlegged versions from Dubai. But in March Mounjaro, a weight-loss drug from Eli Lilly, an American pharmaceutical giant, became legally available in India. In June Wegovy, a drug from Novo Nordisk, a Danish firm, followed. Demand is surging. Though Indians are on average slimmer than people in most other countries, the obese population is one of the largest in the world, along with America's and China's. In Delhi, every fourth resident has Type 2 diabetes. Between 2021 and 2024 Indian sales of weight-loss drugs grew five-fold to $72m. India's market could soon grow to $1bn, predicts Jefferies, an investment bank. This may be a modest share of the $24bn in annual global sales of weight-loss drugs. But as the global market is set to rocket to $150bn in annual sales in the next decade, industry insiders see India as a juicy target. Mounjaro was an instant hit: consumption tripled from March to April, according to one industry tracker. Indian pharma is hoping to cash in. Generic firms, such as Biocon, are already offering weight-loss drugs, such as cheaper versions of an inferior first-generation injectable, liraglutide. Sun Pharma, India's biggest drugs company, hopes to launch its own jab in five years. The Indian market is especially lucrative because those who most need to lose weight are also best placed to pay up. In America, poorer people tend to be fatter. But in India obesity peaks in the most prosperous southern regions and is more common among urban than rural populations. The university-educated are more likely to be obese, too. Indeed, the real boom will come next year. That is when the patent for semaglutide, the active ingredient in Ozempic and Wegovy, expires in India. The country's generics giants, such as Cipla and Lupin, will sprint to produce knock-offs. But to cash in on home turf, Indian drug firms need to beat foreign rivals by adapting a global blockbuster to Indian realities. The first is cost. Starting at around $200 a month, Eli Lilly and Novo Nordisk's Indian offering can cost as little as a fifth of their prices in America. But a year's supply of Mounjaro or Wegovy for a single Indian can still end up being roughly equivalent to the country's GDP per person. Indian generics will slash that figure. Some analysts predict a 95% nosedive. Second, South Asians are unusually genetically predisposed to fatty-liver disease. Novo Nordisk's clinical trials suggest semaglutide might reduce it by 37%. Delivering a drug that caters to the quirks of Indian physiology gives Novo Nordisk a head start. Buckle up Finally, consider logistics. Tirzepatide and semaglutide, the active ingredients in Eli Lilly and Novo Nordisk's products, respectively, are injectables. The jabs require cold storage. That is a tough ask in a hot country with patchy logistics chains. India's Mankind Pharma is expecting trial results by the end of 2025 for what would become India's first oral weight-loss drug that could rival injectables. Both Eli Lilly and Novo Nordisk hope to enter this race with their own versions next year. Whoever makes a good weight-loss pill will prosper, especially in rural India. India is the world's biggest supplier of generic drugs, meeting about 20% of global demand. Low- and middle-income countries across Africa, Latin America and South-East Asia have some of the fastest-rising diabetes rates in the world. Dr Reddy's, an Indian pharma giant, plans to launch a generic version of Wegovy in 87 countries when the patent expires next year. The company is targeting Brazil, Turkey and other emerging markets. India also supplies nearly half the generic drugs Americans consume. For now, America levies no tariffs on them. That could change before American patents start expiring in the next decade. David Ricks, Eli Lilly's CEO, has warned that Donald Trump's tariffs could jack up the price of Indian generics. Mr Trump has spoken of slapping 200% tariffs on pharmaceuticals. On July 30th he threatened a 25% general tariff on India and an unspecified 'penalty' for its stances on trade and Russia. If Indian pharma escapes the fallout, it might yet make America skinny again. Stay on top of our India coverage by signing up to Essential India, our free weekly newsletter.
